Increasing demand for cannabis and lithium
Sales of medical cannabis preparations in German pharmacies are rising rapidly, according to the Federal Association of German Pharmacists' Associations. Around 95,000 recipes were sold over the counter in Germany in 2018. Global sales of cannabinoid therapeutics totaled $53 million. So there's still a lot of air up there. Not least because politicians recognise that taxes can be achieved, but also because the use of leisure time is increasingly being legalised.
Canada has been the first major western country in 2018 to legalize recreational cannabis. In the USA there are ten states and more are to follow. Medical cannabis is allowed there in 33 states. RavenQuest BioMed - http://www.commodity-tv.net/c/search_adv/?v=298816 - is a company with cultivation areas in Canada that has already extended its feelers to Europe. Equipped with a Health Canada sales license, the Markham Facility is expected to produce 4,000 kilograms and the Edmonton Facility 7,000 kilograms annually. Over 8,000 kilograms a purchase contract was concluded.
Another raw material and the companies that own it in their projects may also have a bright future ahead of them: Lithium. Experts assume that lithium production will have to be increased enormously in order to meet demand. About one million tons of the battery raw material are to be used per year until 2025. This is where Millennial Lithium comes in - http://www.commodity-tv.net/c/search_adv/?v=298888.
With its flagship project Pastos Grandes in the lithium triangle in Argentina, the lithium company possesses outstanding battery quality. It is a low-cost brine plant which should be approved before the end of this year. This is followed by financing and construction.
Current corporate information and press releases from RavenQuest BioMed (https://www.resource-capital.ch/en/companies/ravenquest-biomed-inc/) and Millennial Lithium (https://www.resource-capital.ch/en/companies/millennial-lithium-corp/).
In accordance with §34 WpHG, I would like to point out that partners, authors and employees can hold shares in the companies mentioned in each case and therefore there is a possible conflict of interest. Only the German version of these messages applies.
Disclaimer: The information provided does not constitute any form of recommendation or advice. We expressly point out the risks involved in securities trading. No liability can be assumed for damages resulting from the use of this blog. I would like to point out that shares and in particular warrant investments are generally associated with risk. The total loss of the invested capital cannot be excluded. All information and sources are carefully researched. However, no guarantee is given for the correctness of all contents. I expressly reserve the right to make a mistake, in particular with regard to figures and exchange rates, despite the utmost care. The information contained herein has been obtained from sources believed to be reliable but does not claim to be accurate or complete. Due to court rulings the contents of linked external sites are also to answer for (so among other things district court Hamburg, in the judgement of 12.05.1998 - 312 O 85/98), as long as no explicit dissociation from these takes place. Despite careful control of the contents, I do not assume any liability for the contents of linked external sites. The respective operators are solely responsible for their content. The disclaimer of Swiss Resource Capital AG also applies: https://www.resource-capital.ch/en/disclaimer/